Kelley Burridge, PhD, Product Quality Team Leader, OBP, OPQ, CDER, U.S. FDA, discusses the importance of continuous manufacturing for the future.
In part of the session "Continuous Manufacturing and Publication of ICH Q13" at the PDA/FDA Joint Regulatory Conference, Kelley Burridge, PhD, Product Quality Team Leader, OBP, OPQ, CDER, U.S. FDA, discusses the importance of continuous manufacturing for the future.
Burridge: Continuous manufacturing is here. An evolution of pharmaceutical quality over the last several decades started with adoption of risk based approaches, as this analytical Technology and Quality by design have set the stage for adoption of continuous manufacturing. What's needed for approval of continuous manufacturing packages is the same as what's needed for batch processes. A demonstration of pharmaceutical quality demonstrate that you understand your product and your process and that you have the capability to operate a well controlled process, consistent with manufacturer's quality guide.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.